MedTrace Logo

Metastasis-directed Therapy in Castration-refractory Prostate Cancer

NCT04222634 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-12-07

No results posted yet for this study

Summary

The aim is to define the postponement of next line systemic treatment (NEST), by the use of metastasis-directed therapy in patients with oligoprogressive castration-refractory prostate cancer. This will be defined by the NEST-free survival.

Furthermore the investigators will use 18F PSMA PET-CT as investigational imaging, to assess the predictive value and impact on treatment policy.

Conditions

  • Castration-resistant Prostate Cancer

Interventions

OTHER

Radiotherapy (SBRT) and/or surgery (metastasectomy)

Metastasis-directed therapy (surgery and/or radiotherapy) as treatment for oligoprogressive lesions

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Gert De Meerleer, Ph.D., M.D. · UZ Leuven

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-27
Primary Completion
2023-07-25
Completion
2030-01-01

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04222634 on ClinicalTrials.gov